RxDoctor Payments Data

Jay Meyerowitz, MD

Geriatric Medicine · Teaneck, NJNPI 1891892816

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 9.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,124 and has fallen 74.8% since, to $283 in 2025.

$3,399in general payments, 2019–2025

Across 218 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$320
  • Johnson & Johnson$316
  • Teva Pharmaceuticals USA, Inc.$283
  • Amgen$251
  • Avanir Pharmaceuticals, Inc.$221
  • Sunovion Pharmaceuticals Inc.$195
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$3,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,399 in reported general payments places this provider in the 85th percentile of 165 geriatric medicine providers in New Jersey.

See all geriatric medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,723
Medicare patients
109
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$35,634
EliquisApixaban50$34,424
MounjaroTirzepatide18$23,655
XareltoRivaroxaban20$20,428
RexultiBrexpiprazole14$17,226
JanuviaSitagliptin Phosphate14$16,883
NeuproRotigotine12$10,735
EntrestoSacubitril/Valsartan25$7,964
EdarbiAzilsartan Medoxomil16$6,159
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,704
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,262
Atorvastatin Calcium179$2,881
Memantine Hcl ErMemantine Hcl13$2,694
Dabigatran EtexilateDabigatran Etexilate Mesylate24$2,022
Duloxetine Hcl52$1,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$62$35,63422 claims
PfizerEliquis$17$34,42450 claims
Lilly USA, LLCMounjaro$99$23,65518 claims
Johnson & JohnsonXarelto$316$20,42820 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74$17,22614 claims
MerckJanuvia$28$16,88314 claims
NovartisEntresto$20$7,96425 claims
Arbor Pharmaceuticals, Inc.Edarbi$56$6,15916 claims
GSKShingrix$74$3,26214 claims
AbbVieSynthroid$320$1,49924 claims
Almatica Pharma LLCSertraline Hcl$14$39123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 geriatric medicine providers in New Jersey.

Other geriatric medicine in Teaneck

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →